Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.31 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.41 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | CPT1A | P50416 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL434365 | 0.98 | MAPT (0.43) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Hydrochloric Acid SCHEMBL2355625 | 0.95 | MAPT (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| SCHEMBL8010 | 0.95 | BBOX1 (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| SCHEMBL14742785 | 0.95 | BBOX1 (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Water SCHEMBL17373732 | 0.93 | BBOX1 (0.39) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Bromide SCHEMBL8416789 | 0.93 | BBOX1 (0.39) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Hydroxyamine SCHEMBL8584616 | 0.91 | BBOX1 (0.43) | MAPTBBOX1SLC22A16LMNATSHR | |
| Phosphoric Acid SCHEMBL9095324 | 0.88 | BBOX1 (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2TSHR | |
| Glycerin SCHEMBL691939 | 0.85 | SLC22A16 (0.42) | MAPTBBOX1SLC22A16SMN1; SMN2LMNA | |
| Hexane SCHEMBL3645235 | 0.85 | FDPS (0.47) | BBOX1FDPSLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768948-A | Method for synthesizing urine phosphorylcholine in citicoline injection | 山东玉满坤生物科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-6773822-B2 | ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. | TEMPLE-INLAND FOREST PRODUCTS CORPORATION | 2004-08-10 | — | — | US | claimed |
| EP-4393934-A1 | METHOD FOR PRODUCING CYTIDINE-5'-DIPHOSPHATE COMPOUND | Kyowa Hakko Bio Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| CN-113816991-B | Preparation method of choline calcium chloride phosphate | 拓新药业集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | disclosed |
| WO-2023211988-A2 | COMPOSITIONS AND METHODS FOR ANTI-PHOSPHOCHOLINE ACTIVE IMMUNOTHERAPY | DUKE UNIVERSITY (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116768948-A | Method for synthesizing urine phosphorylcholine in citicoline injection | 山东玉满坤生物科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | disclosed |
| EP-3999049-A1 | METHODS USEFUL IN TREATING CANCERS HARBORING A KRAS OR HRAS MUTATION OR AMPLIFICATION | Memorial Sloan Kettering Cancer Center (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-2905361-B1 | METHOD OF FORMING A METAL COATING | TOYOTA MOTOR CO LTD (JP) | 2022-01-05 | — | — | EP | disclosed |
| CN-113816991-A | Preparation method of choline calcium phosphochloride | 新乡拓新药业股份有限公司 | 2021-12-21 | — | — | CN | disclosed |
| WO-2005049293-A2 | CEMENTITIOUS SLAB PRODUCTS HAVING ANTIMICROBIAL PROPERTIES | MICROBAN PRODUCTS COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050106336-A1 | Cementitious slab products having antimicrobial properties | MICROBAN PRODUCTS COMPANY (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005014256-A1 | COMPOSITE MATERIAL HAVING THE APPEARANCE OF NATURAL STONE | COSENTINO, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| US-6773822-B2 | ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. | TEMPLE-INLAND FOREST PRODUCTS CORPORATION | 2004-08-10 | — | — | US | disclosed |
| EP-1421242-A1 | ANTIFUNGAL GYPSUM BOARD | Temple-Inland Forest Products Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6680127-B2 | COMPRISING AN ANTIFUNGAL AGENT AND A RETENTION AID, SUCH AS A SURFACTANT, IN ONE OR MORE PAPER FACINGS. | TEMPLE-INLAND FOREST PRODUCTS, CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030035981-A1 | Antifungal gypsum board | TIN INC. D/B/A TEMPLE-INLAND | 2003-02-20 | — | — | US | disclosed |
| WO-2003012218-A1 | ANTIFUNGAL GYPSUM BOARD | TEMPLE-INLAND FOREST PRODUCTS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20030031898-A1 | Antifungal gypsum board | TIN INC. D/B/A TEMPLE-INLAND | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | PIGO, PIGS, AGPS | CHRM2 4302/4885CHRM1 4491/4885CHRM3 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.